Document is current
Any future updates will be listed below
-
Authors
Miglioranza Scavuzzi, Bruna https://orcid.org/0000-0001-9609-001X
van Drongelen, Vincent https://orcid.org/0000-0002-2090-7617
Kaur, Bhavneet
Fox, Jennifer Callahan
Liu, Jianhua
Mesquita-Ferrari, Raquel A.
Kahlenberg, J. Michelle https://orcid.org/0000-0002-4006-8945
Farkash, Evan A. https://orcid.org/0000-0002-5136-079X
Benavides, Fernando
Miller, Frederick W. https://orcid.org/0000-0003-2831-9593
Sawalha, Amr H.
Holoshitz, Joseph https://orcid.org/0000-0002-6563-0404
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR07080, R33AR073014, R01AR059085, R61AR073014)
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (ES101074, HHSN273201600123P)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases
- License Information
-
More Information
Article History
Received: 22 August 2021
Accepted: 14 July 2022
First Online: 28 July 2022
Competing interests
: J.H. is consulting to Zydus-Cadila, a Licensee of unrelated patents owned by the Regents of the University of Michigan. J.M.K has received grant funding from Q32 Bio, Janssen, Bristol Myers Squibb, and ROME Therapeutics, and Ventus Therapeutics. She has done consulting work for Bristol Myers Squibb, Eli Lilly, GlaxoSmithKlein, Gilead, Aurinia Pharmaceuticals, AstraZeneca, and Lupus Therapeutics. All other authors have no competing interests to declare.
